The silent exclusion: rethinking eligibility and generalizability in clinical trials

Documenti analoghi

• Evening administration of long-acting muscarinic antagonists in COPD – a randomized controlled trial
  di: Pradeesh Sivapalan, et al.
  Pubblicazione: (2025-12-01)
• The silent exclusion: rethinking eligibility and generalizability in clinical trials
  di: Jens-Ulrik Jensen, et al.
  Pubblicazione: (2025-08-01)
• Effect of low climate impact vs. high climate impact inhalers for patients with asthma and COPD-a nationwide cohort analysis
  di: Barbara Bonnesen, et al.
  Pubblicazione: (2024-09-01)
• Treatment with prophylactic oral anticoagulants and the risk of mortality in COVID-19 patients: a nationwide cohort study
  di: Sarah Altaraihi, et al.
  Pubblicazione: (2023-05-01)
• SARS-CoV-2 and risk of psychiatric hospital admission and use of psychopharmaceuticals: A nationwide registry study of 4,585,083 adult Danish citizens
  di: Valdemar Rømer, et al.
  Pubblicazione: (2023-01-01)